MilliporeSigma Articles

  1. 4 Considerations For Overcoming Challenges In Gene Therapy Testing

    With continuously evolving gene therapy regulations and guidance and limited time during development for testing, here are four points to consider when planning product-release testing of your gene therapy product.

  2. The Importance Of Scalability In Viral Vectors

    Diseases that lack a cure, or even treatment, may be addressed with new gene therapeutic classes. This potential has spurred new investments in the drug development and commercialization space.

  3. Data Utilization For Advanced Analytics And Near Real-Time Monitoring

    Control, monitor, and analyze equipment, processes, results, and data in near real time and make data-driven decisions at both the process and plant levels.

  4. Robust Harvest Clarification For Adeno-Associated Viral Vectors

    This article demonstrates that depth filters clarify AAV vectors, helping to overcome the unique separation challenges presented by these important vectors for gene therapy.

  5. Perspectives Of Value-Driven, Integrated Solutions In Gene Therapy

    With an integrated solutions provider, you can leverage a comprehensive suite of advanced technologies and expertise that will facilitate your path to market and benefit you for the lifetime of your product.

  6. Viral Vectors: Are We There Yet?

    What must we do as an industry to continue the momentum of cell and gene therapies and ensure these revolutionary treatments become a reality for patients who need them?

  7. Anticipating The Next Decade Of Gene Therapy

    The next decade will bring improvements including the development of alternative approaches to gene delivery, and advances in upstream and downstream processing, analytical methods and intensified/continuous processing.

  8. Viral Clearance Considerations For Adeno-Associated Virus (AAV) Vectors

    There is no one-size-fits-all model for AAV gene therapy products when it comes to viral clearance studies. Here, we address some of the questions concerning viral clearance studies for AAV vectors.